CONSTRUCTION AND EXPRESSION OF H5N1 INFLUENZA VIRUS HEMAGGLUTININ-SPECIFIC scFv-Fc MONOCLONAL ANTIBODIES IN HEK293T CELLS

Chonlatip Pipattanaboon¹, Khwanchit Boonha¹, Surachet Benjathummarak¹, Pannamthip Pitaksajjakul¹,² and Pongrama Ramasoota¹,²

¹Center of Excellence for Antibody Research (CEAR), ²Department of Social and Environmental Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

Abstract. Monoclonal antibody (MAb) is a key element in the development of rapid test kits for many infectious diseases. Our group previously developed two antigen-binding fragment (Fab) MAbs, H5Fab-6 and H5Fab-9, specific to hemagglutinin (H5 HA) of influenza A virus H5N1, but these Fabs do not have a constant fragment (Fc) portion with which to bind with gold particles in a strip test. In order to overcome this impediment, we joined a single-chain variable fragment (scFv) with an Fc region to produce a scFv-Fc MAb, which was expressed in mammalian HEK293T cells. Specificity and sensitivity of each generated scFv-Fc MAb for H5 HA was tested using western blotting and dot-enzyme-linked immunosorbent assay (dot-ELISA), respectively. Two scFv-Fcs (designated H5scFvFc-6 and H5scFvFc-9) were constructed and purified to near homogeneity with a yield of 12.87 mg/l and 33.56 mg/l, respectively. Western blotting indicated that both scFv-Fcs reacted as expected with H5 HA with a sensitivity of 60 pg of H5 HA. These scFv-Fc MAbs should prove useful in the development of antibody-based diagnostic tools.

Keywords: avian influenza virus, H5N1, HEK293T cell line, heterologous expression, scFv-Fc antibody

INTRODUCTION

Avian influenza viruses (AIVs) are single-stranded, negative-sense RNA influenza A viruses of the family Orthomyxoviridae (Nelson and Holmes, 2007; Yin et al, 2013), which are classified into subtypes according to their hemagglutinin (HA) and neuraminidase (NA) antigens (Webster et al, 1992).

In 1997, the first human case of highly pathogenic avian influenza (HPAI) H5N1 infection was reported in Hong Kong, and several HPAI H5N1 outbreaks since have occurred around the world, resulting in over a billion poultry deaths and causing more than 60% mortality in humans (de Jong et al, 1997; Poovorawan et al, 2013). Currently, many AIV subtypes can produce virulent disease and lead to severe pandemics in humans owing to presence in these viruses of mutations or adapta-
tions allowing person-to-person transmission (Webster et al, 1992; Wong and Yuen, 2006). In response to grave concerns regarding control and surveillance of this deadly disease, various studies have been conducted with the aim of developing vaccines, antiviral drugs, therapeutic treatments, and diagnostic tests (Fang et al, 2007; Hao et al, 2009; Luo et al, 2009; Maneewatch et al, 2009; He et al, 2010; Pitaksajjakul et al, 2010; Zhang et al, 2010; Linke et al, 2011; Zhuang et al, 2011; Zhang et al, 2013).

In order to prevent an epidemic of HPAI, rapid diagnosis of this disease is very important. A diagnosis system is needed that has high sensitivity, specificity and rapid readout, especially one that can differentiate HPAI from low pathogenic avian influenza (LPAI) subtypes (Li et al, 2011). Notably, influenza virus HA is the major target for differentiating between HPAI and LPAI subtypes, and this protein also is useful for producing both therapeutic and diagnostic antibodies (Luo et al, 2009; He et al, 2010; Pitaksajjakul et al, 2010; Linke et al, 2011; Zhuang et al, 2011).

One of the rapid diagnostic tools that has good specificity and high sensitivity for detecting many types of infectious viruses especially at their early phase of infection is antibody-based immunochromatographic strip test (ICT). This method has numerous advantages, such as low cost per test, ease of use, rapid operation, suitability for both untrained and trained user (robustness), portability, and long storage shelf-life (Chen et al, 2008; Cui and Tong, 2008; Charlton et al, 2009). Studies on the development of effective ICTs for influenza virus have emphasized that a pair of monoclonal antibodies (Mabs) targeting HA protein is necessary for successful production of a universal rapid detection kit (He et al, 2010). The lowest reported detection limit for H5N1 influenza virus detection using strip ICT is 0.1-0.5 HA unit (Chen et al, 2008; He et al, 2010).

Recombinant antibody technology is required to prepare MAbs suitable for high-throughput production to meet the increasing demand for such diagnostic reagents; however, many of these recombinant MAbs, such as single chain variable fragment (scFv) and antigen binding fragment (Fab), may have low affinities or lack appropriate functions in the absence of additional engineered components (Jager et al, 2013). However, a scFv-Fc format has sufficient IgG-like properties for use in all current immuno-based assays (Kirsch et al, 2008; Thie et al, 2011; Pohl et al, 2012). Moreover, scFv-Fc can be heterologously expressed in both yeast and mammalian cells suitable for large-scale production with yields of 10-27 g/l (Jager et al, 2013). Hosts of choice in mammalian expression systems are human embryonic kidney (HEK) cell lines, including HEK293, HEK293T, and HEK293E cells, all of which have extensively been employed for transient antibody expression, providing an inexpensive and rapid production platform without requiring laborious generation of stable cell clones (Jager et al, 2013). Thus, transient antibody expression in HEK cells provides a suitable means for small-scale production of recombinant MAbs for the screening phase, and this procedure is able to be scaled-up to produce ≈ 1 g/l of antibodies (Zhang et al, 2011; Jager et al, 2013).

Fab MAbs specific to HA of H5N1 (H5 HA) previously developed at the Center of Excellence for Antibody Research, Faculty of Tropical Medicine, Mahidol University, Bangkok included one specific to influenza A and one to H5N1. However,
because Fabs do not contain the Fc portion required for conjugation with nanogold particles required in a strip ICT, these MAb will have to be constructed to contain an Fc region before they can be further developed for use in a diagnostic test.

Hence, in this study, we constructed two scFv-Fc MAbs from our previously generated Fabs that were selected from a chimeric/human Fab phage display library specific to H5 HA (Pitaksajjakul et al, 2010), expressed them in HEK293T, and following purification determined antibody yield, purity, binding specificity, and detection sensitivity.

MATERIALS AND METHODS

Cell line

HEK293T cells were used for the transient production of scFv-Fcs. Cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) containing glucose with L-glutamine (Hyclone, South Logan, UT) supplemented with 10% (v/v) fetal bovine serum (Hyclone).

Construction of scFv cloning plasmids and scFv-Fc expression vectors

Variable heavy chain (VH) and variable light chain (VL) genes of H5scFvFc-6 and H5scFvFc-9 MAbs were amplified from H5Fab-6 and H5Fab-9 MAbs-pComb3XSS plasmid, respectively using CSCVHo-FL and CSCG-B primers for amplification of VH and CSCVK and CKJo-B primers for VL (Andris-Widhopf et al, 2000). Gel-purified VH and VL amplicons were ligated using overlapping PCR method (Andris-Widhopf et al, 2000), subjected to additional gel-purification and inserted into pGEMT easy vector (to generates scFv-pGEMTs) (Promega, Madison, WI). Primers and PCR conditions used in the study are shown in Table 1. The scFv-pGEMTs plasmids then were used as template for each PCR with LS-scFv-Fc Fw and LS-scFv-Fc Rv primers to amplify scFv containing restriction sites. These scFv amplicons and pcFcBR, a pcDNA expression vector containing human Fc region, were digested with HindIII and BamHI (New England BioLabs, Hitchin, UK), and followed by ligation with T4 ligase (New England BioLabs). All DNA constructs were verified by restriction enzyme mapping and DNA sequencing (Macrogen Korea, Seoul, Korea).

Expression and purification of H5scFvFc-6 and H5scFvFc-9 MAbs

Constructed plasmids of H5scFvFc-6 and H5scFvFc-9 MAbs were transfected into HEK293T cells, which were seeded at a concentration of 5×10^5 cells/ml one day before transfection in a T75 flask containing 15 ml of the above DMEM culture medium and incubated at 37°C under an atmosphere of 5% CO₂. FuGENE HD (Promega) was used as transfection agent at a ratio of 3:1 FuGENE:DNA following the manufacturer’s recommendations. Culture supernatants (15 ml) of transfected HEK293T cells containing the expressed scFv-Fc MAbs were collected from day 2 to day 14, being replaced with 15 ml of new culture medium every 3 days. The scFv-Fc MAbs were purified from supernatants using Protein A affinity column (GE, Uppsala, Sweden). Protein concentration was measured using Pierce™ BCA Protein Assay Kit (Thermo Scientific, Rockford, IL).

SDS-PAGE analysis of purified scFv-Fc MAbs

Five µl aliquots of purified scFv-Fc MAbs were mixed with sample buffer without β-mercaptoethanol, incubated at 95°C for 5 minutes, and analyzed by 10%
Table 1
Primer sequences and PCR conditions used in scFv-Fc construction.

<table>
<thead>
<tr>
<th>Target</th>
<th>Primer</th>
<th>Sequence (5’-3’)</th>
<th>PCR components</th>
<th>Thermocycling condition</th>
</tr>
</thead>
<tbody>
<tr>
<td>( V_H )</td>
<td>CSCVHo-FL</td>
<td>GGTCA\textsc{T}T\textsc{T}CTAGAT\textsc{T}CTTGGG \textsc{G} C</td>
<td>Final volume: 25 µl</td>
<td>• 94°C, 5 minutes</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CAGGCGGCCCTGACTAGTGGAGG \textsc{G}</td>
<td>2.5 µl of 10X PCR buffer plus MgCl(_2)</td>
<td>• 30 cycles: 94°C for 15 s, 60°C for 15 s, and 72°C for 2 minutes</td>
</tr>
<tr>
<td></td>
<td>CSCG-B</td>
<td>GAGGACATCGTGGCCACTAGTGGAGG \textsc{C}</td>
<td>0.5 µl of 10 mM dNTP mix</td>
<td>72°C, 10 minutes.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>15 pmol of each primer</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.5 U Hi-fidelity DNA polymerase (Roche, Germany)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>50 ng of each Fab template.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>( V_L )</td>
<td>CSCVK</td>
<td>GTGGCCCGGCGCCTGACTAGTGGAGG \textsc{C}</td>
<td>Final volume: 25 µl</td>
<td>• 94°C, 5 minutes</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CAGGCGGCCCTGACTAGTGGAGG \textsc{G}</td>
<td>2.5 µl of 10X PCR buffer plus MgCl(_2)</td>
<td>• 30 cycles: 94°C for 15 s, 60°C for 15 s, and 72°C for 2 minutes</td>
</tr>
<tr>
<td></td>
<td>CkJo-B</td>
<td>GAGGACATCGTGGCCACTAGTGGAGG \textsc{G}</td>
<td>0.5 µl of 10 mM dNTP mix</td>
<td>72°C, 10 minutes.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>15 pmol of each primer</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.5 U Hi-fidelity DNA polymerase (Roche, Germany)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>50 ng of each Fab template.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>( scFv )</td>
<td>CSC-F</td>
<td>GAGGAGAGAGAGAGAGAGG \textsc{G}</td>
<td></td>
<td>First round:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CAGGCGGCCCTGACTAGTGGAGG \textsc{C}</td>
<td>94°C for 5 minutes</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>2.5 µl of 10X PCR buffer plus MgCl(_2)</td>
<td>20 cycles: 94°C for 15 s, 56°C for 15 s, and 72°C for 1 minute</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.5 µl of 10 mM dNTP mix</td>
<td>4°C.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.5 U Hi-fidelity DNA polymerase (Roche, Germany)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>100 ng of purified ( \text{V}_L ) and ( \text{V}_H ) template</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>No addition of primers.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CSC-F</td>
<td>GAGGAGAGAGAGAGAGG \textsc{G}</td>
<td>Second round:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>CAGGCGGCCCTGACTAGTGGAGG \textsc{C}</td>
<td>20 cycles: 94°C for 15 s, 56°C for 15 s, and 72°C for 2 minutes</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>15 pmol of CSC-F and CSC-B primers</td>
<td>72°C for 10 minutes.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.5 µl of 10 mM dNTP.</td>
<td>94°C for 5 minutes</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.5 U Hi-fidelity DNA polymerase (Roche, Germany)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>( scFv-Fc )</td>
<td>( LS_{scFV_{Fc}} )</td>
<td>GAGGAGAGAGAGAGAGG \textsc{G}</td>
<td>Final volume: 25 µl</td>
<td>30 cycles: 94°C for 15 s, 56°C for 15 s, and 72°C for 2 minutes</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ATGAGCGTGGCCCTACCAGTGGG \textsc{G}</td>
<td>15 pmol of both primers</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.5 U Hi-fidelity DNA polymerase (Roche, Germany)</td>
<td>72°C for 10 minutes.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>50 ng of each Fab template.</td>
<td>94°C for 5 minutes</td>
<td></td>
</tr>
</tbody>
</table>
SDS-PAGE at 100 V. Protein bands were stained with Coomassie brilliant blue R-250 dye (Thermo Scientific).

**Dot blot analysis of expressed scFv-Fc MAbs**

Three μl aliquot of culture fluid taken every 3rd day was dotted onto a polyvinylidene difluoride (PVDF) membrane (GE), treated with 5% skim milk at room temperature for 2 hours, then incubated with goat anti-human IgG (H+L) conjugated with horseradish peroxidase (HRP) (1:2,500 dilution) (KPL, Gaithersburg, MD) at room temperature for 1 hour, and stained with 3, 3’ diaminobenzidine (DAB) reagent set (KPL).

**Western blot analysis of scFv-Fc MAbs specificity**

Two scFv-Fc MAbs were tested for specific binding to recombinant H5 HA derived from H5N1 AIV strain A/Vietnam/1203/04 (from an insect cell expression system) (Stevens et al, 2006). H5 HA (500 ng) was mixed with sample buffer containing β-mercaptoethanol (Thermo Scientific), subjected to 10% SDS-PAGE as described above, transferred onto PVDF membrane, treated as described above before being incubated with each scFv-Fc MAb at 4°C overnight followed with incubation with HRP-conjugated goat anti-human IgG (H+L) (1:2,500 dilution at room temperature for 1 hour and visualized using DAB reagent set.

**Dot-ELISA test of scFv-Fc MAbs sensitivity**

A 10-fold serial dilution of H5 HA (from 20 to 2 pg/μl) was used to determine sensitivity of each scFv-Fc MAb. Three μl aliquots of H5 HA samples were dotted onto PVDF membrane strip, treated with 5% skim milk at room temperature for 2 hours, incubated with each prepared scFv-Fc MAb (500, 50, 5, 0.5, and 0.05 ng/ml) at 4°C overnight, then incubated with
HRP-conjugated goat anti-human IgG (H+L) (1:2,500 dilution) at room temperature for 1 hour and visualized using DAB reagent set.

RESULTS

Construction of scFv and scFv-Fc plasmids for scFv-Fc antibody expression

We engineered H5Fab-6 (H5N1-specific) and H5Fab-9 (influenza A-specific) Fab antibody fragments into the corresponding scFv-Fc molecules because adding an Fc portion to these MAb would make them more useful for future applications, such as ICT development. \( V_H \) and \( V_L \) was amplified from Fab-pComb3XSS vector that encodes the respective Fab generating the expected amplicon of 400 and 350 bp, respectively (Fig 1A). These amplicons were then ligated by means of overlapping PCR and inserted into pGEMT to generate scFv-pGEMTs carrying the expected 750 bp fragment (Fig 1B). After sequence confirmation, scFv portion of scFv-pGEMT was amplified, restriction digestion and inserted into pcFcB-R carrying the expected 900 bp fragment (Fig 1C).

Transient expression of scFv-Fc IgG-like MAb in HEK293T cells

In order to assess successful engineering of the scFv-Fc expression vectors, HEK293T cells were transfected with each constructed plasmid using FuGENE HD reagent and cultured for 14 days. Dot blot analysis of scFv-Fc MAb in culture medium every 3 days showed that scFv-Fc was produced in HEK293T cells from day 2 post-transfection (Fig 2). ScFv-Fc MAb in culture medium was purified using Protein A affinity chromatography and analyzed by SDS-PAGE, demonstrating production of scFv-Fc (230 kDa) with near homogeneity (Fig 3). The yield of H5scFvFc-6 and H5scFvFc-9 was 12.9 and 33.6 mg/l, respectively.

Specificity and sensitivity of scFv-Fc MAb binding to H5 HA

In order to determine if these scFv-Fcs are suitable for diagnostic application, we tested their specific binding to the antigen,
Generation of H5N1 Specific scFv-Fc Antibodies

H5 HA, recognized by the original Fabs. Under sulfhydryl reducing conditions, both H5scFvFc-6 and H5scFvFc-9 reacted with the 50 kDa H5 HA antigen as demonstrated by western blotting (Fig 4).

Limit of H5 HA detection by these two antibodies was evaluated using dot-ELISA, which showed a detection limit of 60 pg for both scFv-Fc antibodies (500 ng/ml) (Fig 5).

DISCUSSION

The aim of this study was to develop new MAbs for detecting AIV H5N1, with the ultimate goal of applying these MAbs to the creation of a strip ICT kit. In the previous work, two groups of Fab MAbs specific to influenza virus HA were generated: one group specific to AIV H5N1 and the other cross-reactive with several influenza A subtypes, including H5N1, H1N1, H3N2, and H9N2 (Pitaksajjakul et al, 2010). In order to develop a new rapid detection strip ICT with high specificity and sensitivity from these two groups of Fab MAbs, each of which recognizes a different epitope from that of existing ICTs, we plan to use H5N1-specific H5Fab-6 as the immobilized antibody on the test line and cross-reactive H5Fab-9 as the antibody conjugated to gold particle (He et al, 2010). Preliminary studies indicated that these two Fab MAb molecules were too short to bind to gold particles in an ICT. In order to make use of the Fab portion that contains the binding region to HA, we needed to lengthen the Fab molecules. We chose the scFv-Fc format because it contains both an Fc region, capable of conjugating with gold particles, and scFv region for binding with HA. Additionally, the scFv-Fc antibody format can be used in many types of immunoassays, such as ELISA (Thie et al, 2011), immunoblot (Kirsch et al, 2008) and surface Plasmon resonance (Thie et al, 2011; Pohl et al, 2012).

H5scFvFc-6 and H5scFvFc-9 MAbs were constructed using two of the nine Fab MAb clones that were previously produced (Pitaksajjakul et al, 2010). H5Fab-6 is highly specific to H5N1 influenza virus, and H5Fab-9 cross-reacts with influenza A subtypes (Pitaksajjakul et al, 2010). Recombinant H5Fab-6 and H5Fab-9 plasmids were used as DNA templates to amplify \( V_H \) and \( V_L \) coding regions for construction of scFvs DNA fragments. Each scFv gene, encoding one \( V_H \) and one \( V_L \) chain of immunoglobulin connected by a peptide linker, was then fused with an IgG Fc gene

<table>
<thead>
<tr>
<th>Secreted MAbs</th>
<th>Day 2</th>
<th>Day 5</th>
<th>Day 8</th>
<th>Day 11</th>
<th>Day 14</th>
</tr>
</thead>
<tbody>
<tr>
<td>H5scFvFc-6</td>
<td><img src="image1.png" alt="Image" /></td>
<td><img src="image2.png" alt="Image" /></td>
<td><img src="image3.png" alt="Image" /></td>
<td><img src="image4.png" alt="Image" /></td>
<td><img src="image5.png" alt="Image" /></td>
</tr>
<tr>
<td>H5scFvFc-9</td>
<td><img src="image6.png" alt="Image" /></td>
<td><img src="image7.png" alt="Image" /></td>
<td><img src="image8.png" alt="Image" /></td>
<td><img src="image9.png" alt="Image" /></td>
<td><img src="image10.png" alt="Image" /></td>
</tr>
</tbody>
</table>

Fig 2–Heterologous expression of scFv-Fc MAbs by HEK293T cells. Cells were cultured in a T75 flask following FuGENE HD assisted transfection with H5scFvFc-6 or H5scFvFc-9. Western dot blot analysis was performed on culture fluid obtained from day 2 to day 14 post-transfection to determine amount of secreted antibody.
Fig 3–SDS-PAGE profiles of affinity purification of H5scFvFc-6 and H5scFvFc-9 MAbs. H5scFvFc-6 (upper panel) and H5scFvFc-9 (lower panel) fractions eluted from Protein A affinity column were resolved in a 10% SDS-PAGE and stained with Coomassie blue dye. Left lane, pre-stained protein size marker (10-230 kDa) (NEB).

To generate a scFv-Fc gene. This scFv-Fc coding construct was reported previously to have similar properties to those of native IgG (Shu et al, 1993; Moutel et al, 2009).

The scFv-Fc MAbs were expressed in a mammalian HEK293T cell line, widely used for heterologous protein expression (Ho and Pastan, 2009). HEK293T cell heterologous protein expression relies on transfection with DNA encoding the gene of interest (Schenk et al, 2007). In the small pilot scale of this study (15 ml in a T75 flask), the production yields were in the appropriate range for small-scale transient scFv-Fc expression (10-20 mg/l) (Jager et al, 2013), but the generation of a stable cell expression system, which can produce higher yields (Chusainow et al, 2009) is in progress. Furthermore, HEK293T cells can be very efficiently transfected with plasmids, and their ability to folding, modify and secrete heterologously expressed proteins (Schenk et al, 2007) make them well-suited for antibody production. The antibodies expressed by HEK293T cells generally contain post-translational modifications required for their function (Schenk et al, 2007). In addition, the use of a helper reagent during transfection, such as FuGENE HD or lipofectamine, is also important. In this study, FuGENE HD, a non-liposomal reagent that functions by complexing with nucleic acids, was used, allowing plasmids to overcome the electrostatic
Generation of H5N1 Specific scFv-Fc Antibodies

Fig 4–Specificity assay of H5scFvFc-6 and H5scFvFc-9 MAbs. Binding of H5scFvFc-6 and H5scFvFc-9 MAbs to 500 ng of H5 HA (50 kDa) was assessed by western blotting. Left lane, pre-stained protein size markers.

Fig 5–Sensitivity assay of H5scFvFc-6 and H5scFvFc-9 MAbs. Binding capacity of H5scFvFc-6 and H5scFvFc-9 to H5 HA (3 µl per spot) was determined by dot-ELISA. At 500 ng/ml, both scFv-Fcs showed a limit of detection of 60 pg of H5 HA antigen.

repulsion of the cell surface and to be efficiently taken up by cells (Chen et al, 2013). Our optimization experiments indicated that a ratio of FuGENE HD: scFv-Fc plasmid of 3:1 in a 24-well plate (data not shown) was optimal for expression, and this ratio will be employed in the scale-up experiments.

Western blotting assay performed with 500 ng of H5 HA confirmed the specificity of both scFv-Fc MAbs. Dot-ELISA showing a detection limit of both scFv-Fc MAbs at 20 pg/µl (60 pg) is similar to that of Fab MAbs (Pitaksajjakul et al, 2010). Given that both antibodies showed good specificity and high sensitivity with H5 HA, this combination of antibodies
may be promising for use in the detection of H5N1 infection. While there are many studies on the development of scFv MAbs specific to H5N1 influenza virus hemagglutinin (Fang et al, 2007; Hao et al, 2009; Maneewatch et al, 2009; Zhang et al, 2010, 2011, 2013), this is the first study to develop scFv-Fc specific to HA of H5N1 virus.

In summary, two scFv-Fc MAbs were successfully constructed from Fab MAbs, and both are specific to H5 HA with the requisite sensitivity. The inclusion of the Fc portion in these scFv-Fc MAbs will allow binding of gold particles, a necessary property for the development of strip ICT. Future work will aim at producing a clinically useful strip ICT employing the constructed scFv-Fc MAbs.

ACKNOWLEDGEMENTS

The authors thank Dr James Petterson for providing pcFcB-R vector and Dr Ian A Wilson for providing recombinant H5 HA. This study was supported by The Thailand Research Fund (grant number RSA56).

REFERENCES


Linke S, Neubauer K, Dorner MB, Dorner BG, Pauli G, Schweiger B. Generation and


